Results 71 to 80 of about 180 (117)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis

Neuropsychiatric Disease and Treatment, 2010
Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system.
Julie A Murphy, Jacklyn A Harris, Andrew J Crannage   +2 more
doaj  

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

Frontiers in Immunology
IntroductionPediatric-onset multiple sclerosis (POMS) poses unique therapeutic challenges due to high inflammatory activity, early cognitive and psychosocial impact, and difficulties with long-term treatment adherence.
Esther Ganelin-Cohen, Esther Ganelin-Cohen, Yair Wexler, Sraya Kraus, Sraya Kraus, Ayal Rozenberg, Ayal Rozenberg   +6 more
doaj   +1 more source

Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells

Clinical Immunology
Abstract Recently it has been shown that treatments targeting B cells in multiple sclerosis (MS) are effective in controlling disease activity. B cells contribute to the pathogenesis of MS via antigen presentation, T cell activation, and antibody production.
Francesca Ammoscato, Mohammad Aboulwafa, Justyna Skonieczna, Jonathan Bestwick, Rosemary Monero, Michael Andrews, Stefania De Trane, David Holden, Ashok Adams, Lucia Bianchi, Ben Turner, Monica Marta, Klaus Schmierer, David Baker, Gavin Giovannoni, Sharmilee Gnanapavan   +15 more
openaire   +2 more sources

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

Therapeutic Advances in Neurological Disorders, 2018
Background The CLARITY and CLARITY Extension studies demonstrated that treatment of relapsing–remitting multiple sclerosis (RRMS) with cladribine tablets (CT) results in significant clinical improvements, compared with placebo.
Giancarlo Comi, Stuart Cook, Kottil Rammohan, Per Soelberg Sorensen, Patrick Vermersch, Abidemi K. Adeniji, Fernando Dangond, Gavin Giovannoni   +7 more
doaj   +1 more source

ePresentation

European Journal of Neurology, Volume 32, Issue S1, June 2025.
wiley   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 32, Issue S1, June 2025.
wiley   +1 more source

Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy

Journal of Neurology
Abstract Oral cladribine is a highly effective pulsed selective immune reconstitution therapy (SIRT) that received approval for the treatment of relapsing multiple sclerosis (RMS) in 2017. The concept of SIRT is characterized by brief exposure to active substances with long-term effectiveness, repopulation of lymphocytes, and ...
C. Kleinschnitz, T. Skripuletz, S. Pfeuffer, M. Pawlitzki, P. Rieckmann, I.-K. Penner, J. Knaup, T. Wagner, M. Hübschen, K. Hellwig, R. Pul   +10 more
openaire   +2 more sources

Summary of Research: Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the Global MAPLE-MS Pharmacovigilance Program

Neurology and Therapy
Information on pregnancy and infant outcomes after cladribine tablets exposure is limited, as its use is not recommended during pregnancy. This is a summary of the original published article ‘Pregnancy and infant outcomes in multiple sclerosis: findings ...
Kerstin Hellwig, Hugh H. Tilson, Sandra Thiel, Kathryn Ball, Joerg Seebeck, Muriel Danten, Nancy Dubois, Meritxell Sabidó   +7 more
doaj   +1 more source

Treatment-free remission in MS: long-term disease control with cladribine tablets

Journal of Neurology
Abstract Oral cladribine, a highly effective pulsed selective immune reconstitution therapy (SIRT) for relapsing multiple sclerosis (RMS) is characterised by extended treatment-free periods following brief exposure to medication. Since approval in 2017, long-term real-world data have become available which provide insight into the ...
Heinz Wiendl, Ralf Gold, Refik Pul, Michael Ernst, Markus C. Kowarik, Juliane Klehmet, Ines Siglienti, Michael Hübschen, Torsten Wagner, Judith Knaup, Christoph Kleinschnitz   +10 more
openaire   +3 more sources

Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar

Clinical Neurology and Neurosurgery
To study the 30-month safety and effectiveness of Cladribine tablets (CladT) in relapsing multiple sclerosis (RMS) months in a real-world setting.Retrospective single-centre observational study in Qatar (January 2018-Feb 2023). Clinical and MRI data, lymphocyte counts and adverse events (AE) were recorded for patients with RMS who received at least one
Beatriz Garcia Cañibano, Lina Okar, Yahya Zakarya Baniamer, Dirk Deleu   +3 more
openaire   +2 more sources